Posted by on February 22, 2018 10:59 pm
Categories: Crispr Articles

Source: Webinar archive: Genome editing, CRISPR, and what comes next


TAT senior science writer Sharon Begley and national biotech columnist Adam Feuerstein tell us what CRISPR is (and is not), what other genome-editing methods are already being tested, and which companies are betting on these technologies to one day treat, cure, or prevent disease.

This is the year when CRISPR will move out of the lab and into patients in the first U.S. clinical trials of the genome-editing technology. See what Sharon, Adam, and webinar participants think success might look like.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It’s easy! Your first 30 days are free and if you don’t enjoy your subscription you can cancel any time.

Already a subscriber? Log in here.

Published at Thu, 22 Feb 2018 20:46:21 +0000

Leave a Reply